Multiple Clinical Trial Data for Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, to be Presented at ADA 2026
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that data from a Phase 1b study conducted in China evaluating elecoglipron (AZD5004/ECC5004), an oral small-molecule GLP-1 receptor agonist, will be presented in a late-breaking poster presentation at the 2026 Scientific Sessions of the American Diabetes Association® (ADA). The ADA’s 2026 Scientific Sessions will take place June 5-8 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.
Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MIST, the company’s Phase 2a clinical trial evaluating ECC4703 as an adjunct to semaglutide in adults with obesity.
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced positive topline results from the first Phase 1b clinical trial in China evaluating elecoglipron (AZD5004/ECC5004) in adults living with obesity or overweight, with or without type 2 diabetes mellitus (T2DM).
Eccogene Announces First Patient Enrolled in MOSAIC Phase 2a Trial Evaluating ECC4703 and ECC0509, Individually and in Combination, for the Treatment of MASH
Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions, today announced that the first patient has been enrolled in MOSAIC, the company’s Phase 2a clinical trial evaluating ECC4703, ECC0509 and their combination in adults with MRI-based or clinically defined metabolic dysfunction-associated steatohepatitis (MASH). The MOSAIC trial is designed to evaluate two differentiated mechanisms, THR-β agonism and SSAO inhibition, and to determine whether each monotherapy provides meaningful metabolic or inflammatory benefit.
